Lilly’s Omvoh Leads the GI Biologics in the Canadian and European Markets in Q4 

AbbVie highlighted its commitment to patient care through the AbbVie Care Support Program in Canada, while Europe noted the use of the fecal calprotectin test as a non-invasive biomarker and multidisciplinary collaboration for IBD management.

Johnson and Johnson introduced Finlius in Canada as an alternative to Stelara. The European market focused on convenient administration via the One-Press device.

Lilly’s Omvoh featured sustained remission and symptom improvement with the results of multiple clinical studies across Europe and Canada. The “Make the Invisible Visible” initiative and the “Colored Suitcases” theme were introduced.

Takeda paid particular attention to Entyvio’s 10-year milestone and clinical experience in Canada, while efficacy based on clinical studies was noted in both continents. The VDZ-CDST algorithm and the importance of mental health were emphasized.